Therapeutic Solutions International Utilizes Mesenchymal Stem Cell Exosomes to Effectively Suppress Neutrophil Extracellular Trap Production

Rhea-AI Summary

Therapeutic Solutions International, Inc. (OTC Markets: TSOI) announced lab data showing that exosomes from JadiCells™, the Company's Phase III COVID-19 therapy candidate, can inhibit neutrophil extracellular trap production. These traps are linked to inflammation in conditions such as COVID-19 and cancer. The findings support a patent application and suggest potential for new treatments for inflammation-related diseases. Dr. James Veltmeyer highlighted the rapid translation of this discovery into applications, while Timothy Dixon emphasized the opportunity for First in Class approaches for big pharma partnerships.

Positive

• Lab data indicates JadiCells™ exosomes can suppress inflammation-related neutrophil traps.
• Potential for rapid translation into treatment applications for various diseases.
• Preliminary data suggests potent lung protective activity in animal models.

Negative

• None.

ELK CITY, Idaho, Oct. 4, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced today laboratory data demonstrating that exosomes produced by JadiCells™, the Company's Phase III cell therapy candidate for COVID-19 and other lung pathology, as well as mesenchymal stem cells proprietary to the Company, can suppress the production of neutrophil extracellular traps.

Neutrophil extracellular traps are a network of extracellular DNA, histones, and enzymes that cause inflammation. In healthy individuals, neutrophil extracellular traps are very useful in fighting bacterial infections. Unfortunately, in conditions such as COVID-19, atherosclerosis, cancer, and various autoimmune diseases, neutrophil extracellular traps are considered to play a major role in disease initiation and progression¹. 

In a series of experiments JadiCells and other mesenchymal stem cells were stimulated using agents that replicate biological "danger signals".  It was observed that the cells produced exosomes, which when added to neutrophils, would inhibit the production of neutrophil extracellular traps. The experimental data is part of a patent application that was submitted today.

"Due to the small size of exosomes, their ease of production, and the fact that they are made from stem cells that are recognized by the FDA, we anticipate rapid translation of this new approach into potential treatments for a variety of inflammation associated conditions," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "Preliminary data suggests that the exosomes themselves possess potent lung protective activity in animal models of lung injury simple to COVID-19. This gets us excited because it opens the possibility for increasing our product pipeline."

"The lifeblood of our Company is the germination of thought into working applications. The findings described today are particularly exciting to us because they point to a potentially new mechanism by which stem cells, and the exosomes they produce, affect inflammation," said Timothy Dixon, President and CEO of the Company and co-inventor. "By targeting broadly acting molecular targets we have the opportunity to develop First in Class approaches towards diseases, which have significant possibility of sale or partnership with Big Pharma."

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Jorge and Kubes. An emerging role for neutrophil extracellular traps in noninfectious disease.  Nat Med. 2017 Mar 7;23(3):279-287

ir@tsoimail.com

View original content:https://www.prnewswire.com/news-releases/therapeutic-solutions-international-utilizes-mesenchymal-stem-cell-exosomes-to-effectively-suppress-neutrophil-extracellular-trap-production-301391625.html

SOURCE Therapeutic Solutions International

FAQ

What are the latest findings from Therapeutic Solutions International regarding TSOI?

The company announced lab data showing JadiCells™ exosomes can inhibit neutrophil extracellular trap production, potentially aiding in inflammation-related conditions.

How might TSOI's findings affect COVID-19 treatments?

The data suggests that JadiCells™ may offer new therapeutic options for COVID-19 by targeting inflammation.

Is there a patent application related to TSOI's recent findings?

Yes, the experimental data supporting the findings is part of a patent application submitted by Therapeutic Solutions International.

What are neutrophil extracellular traps and their significance in TSOI's research?

Neutrophil extracellular traps are linked to inflammation and disease progression, particularly in COVID-19, making their suppression important for potential therapies.